Menu
Back to Journals » OncoTargets and Therapy » Volume 13
RNA-Binding Motif Protein 38 as a Potential Biomarker and Therapeutic Target in Cancer
Authors She X, Lin Y, Liang R, Liu Z, Gao X, Ye J
Received 31 August 2020
Accepted for publication 27 November 2020
Published 24 December 2020 Volume 2020:13 Pages 13225—13236
DOI https://doi.org/10.2147/OTT.S278755
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Dr Leo Jen-Liang Su
Xiaomin She, Yan Lin, Rong Liang, Ziyu Liu, Xing Gao, Jiazhou Ye
Medical Oncology, Guangxi Medical University Cancer Hospital, Nanning, People’s Republic of China
Correspondence: Jiazhou Ye Tel +86 7715301253
Email nnsz20013@163.com
Abstract: RNA-binding proteins (RBPs) act as a key factor in gene regulation by governing RNA metabolism. They contribute to the expression and functions of most RNAs by binding to them and forming complexes. RNA-binding motif protein 38 (RBM38), a member of the RBP family, alters the stability and translation of targeted mRNAs to affect various biological processes, such as cell proliferation, cell cycle arrest, and myogenic differentiation. RBM38 contains a highly conserved RNA recognition motif (RRM) consisting of two subunits, RNP1 and RNP2, which specifically bind to RNAs. Recent studies have revealed that RBM38 regulates the mRNA stability of several tumor-related genes, such as p53, mdm2, p63, p73, p21, and c-Myc, by binding to their 3′ untranslated regions (3′ UTRs); thus, RBM38 modulates targeted gene expression and affects the biological processes of tumors. In addition, abnormal RBM38 expression in some malignant tumors and its correlation with prognosis have been documented in many studies, indicating its value for potential clinical applications. In this review, we present an overview of RBM38, specifically highlighting its relationship with tumor manifestation and development. A brief overview of the potential use of RBM38 in cancer therapy is also included to provide ideas for further research on RBM38.
Keywords: RBM38, malignant tumors, p53 family, posttranscriptional regulation
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.
By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.